All entries for: Gut-Brain Axis Therapeutics

Gut-Brain Axis Therapeutics raised $1.97 million to advance its microbiota transplant therapy (MTT), an FDA-designated orphan drug in clinical development for the treatment of Pitt-Hopkins Syndrome, a rare and severe neurodevelopmental disorder.